CHST1 Drives Immunotherapy Resistance in Triple‐Negative Breast Cancer by Orchestrating an Immunosuppressive Microenvironment via the NKRF–CCL20–Macrophage Axis
Mechanical analyses support a CHST1–NKRF–CCL20 regulatory model and identifies CCR6 blockade as a potential therapeutic strategy and a CHST1–NKRF–CCL20 expression signature showed potential value for stratifying immunotherapy response.